J Cancer 2017; 8(9):1542-1551. doi:10.7150/jca.18680

Research Paper

MicroRNA-765 Enhances the Anti-Angiogenic Effect of CDDP via APE1 in Osteosarcoma

Wei Liang1*, Xi Wei2*, Qing Li1, Nan Dai1, Chong-Yi Li1, Yi Deng, Xuan Jiang1, Xiao-Rong Tan1, Xiao-Yan Dai1, Meng-Xia Li1, Cheng-Xiong Xu1, Dong Wang1, Zhao-Yang Zhong1 ✉

1. Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing,400042, China;
2. Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key laboratory of Cancer Prevention and Therapy, Tianjin, China.
* These authors Wei Liang and Xi Wei contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Liang W, Wei X, Li Q, Dai N, Li CY, Deng Y, Jiang X, Tan XR, Dai XY, Li MX, Xu CX, Wang D, Zhong ZY. MicroRNA-765 Enhances the Anti-Angiogenic Effect of CDDP via APE1 in Osteosarcoma. J Cancer 2017; 8(9):1542-1551. doi:10.7150/jca.18680. Available from http://www.jcancer.org/v08p1542.htm

File import instruction


Human osteosarcoma (HOS) is the most common malignancy in children and adolescents and has a heterogeneous presentation and high mortality. Previous studies have shown that microRNAs contribute to RNA silencing and post-transcriptional regulation of gene expression. Here, we showed that significantly increased expression of miR-765 with or without CDDP (Cisplatin) down-regulates APE1 expression and angiogenesis-related markers (VEGF, FGF2, TGFβ, and CD34). Further investigation showed that miR-765 modulates osteosarcoma cell migration and angiogenesis following treatment with cisplatin in vitro and in vivo. MiR-765 increases the anti-angiogenic effect of CDDP in human osteosarcoma. Elucidation of the mechanism of the miR-765-APE1 axis in tumor progression of HOS will be beneficial in identifying biomarkers and therapeutic target of osteosarcoma.

Keywords: MicroRNA-765, APE1, Cisplatin, Anti-angiogenesis, Osteosarcoma.